middle.news

Tissue Repair Launches Pivotal Phase 3 Trial for TR987® in Chronic Wound Care

7:03pm on Monday 2nd of June, 2025 AEST Biotechnology
Read Story

Tissue Repair Launches Pivotal Phase 3 Trial for TR987® in Chronic Wound Care

7:03pm on Monday 2nd of June, 2025 AEST
Key Points
  • Phase 3 trial initiated with 600 participants across Australia and the US
  • TR987® showed significant healing improvements in Phase 2 trials
  • Trial involves major hospitals including Royal North Shore and Northwell Health
  • Chronic wounds affect millions globally, with high healthcare costs
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about Tissue Repair (ASX:TRP)
OPEN ARTICLE